Newsletter | June 25, 2026

06.25.26 -- What To Do About Process Drift In Your Biosimilar's Reference Product

INDUSTRY INSIGHTS

Helpful Biosafety Testing Innovations Where And When You Need Them

Monoclonal antibody manufacturing is advancing to boost efficiency, cut costs, and expand access, driven by innovation, demand, and the rise of biosimilars.

FEATURED EDITORIAL

Rethinking CQV In A Digital, Agile Manufacturing Landscape

While commissioning, qualification, and validation (CQV) remains foundational, the way it is planned and executed must evolve to keep pace with modern manufacturing realities.

Field Notes: Freeing Process Data For Automation At Kivi Bio AI Summit

The missing link between data generation and unleashing it to power automation often lies in well-governed cloud infrastructure.

What To Do About Process Drift In Your Biosimilar's Reference Product

Biosimilar development often reveals quality drifts in certain lots of the reference biologic. In most cases, quality changes are noncritical, but some drifts can impact CQAs.

SOLUTIONS

Control Software For Industrial Applications